|1.||Bai, Shaochun: 1 article (05/2004)|
|2.||Goodrich, David W: 1 article (05/2004)|
|3.||Woynarowski, Jan M: 1 article (11/2003)|
|4.||Herman, Terence S: 1 article (11/2003)|
|5.||Jackson, Jennifer A: 1 article (11/2003)|
|6.||Herzig, Maryanne C: 1 article (11/2003)|
|7.||Trevino, Alex V: 1 article (11/2003)|
|8.||Melendy, Thomas: 1 article (07/2003)|
|9.||McHugh, Mary M: 1 article (07/2003)|
|10.||Beerman, Terry: 1 article (07/2003)|
01/01/1994 - "Bizelesin (U-77779) is a highly potent bis-alkylating antitumor agent that is effective against several tumor systems in vitro and in vivo. "
03/01/2002 - "A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors."
03/01/2002 - "Patients with advanced solid tumors received escalating doses of bizelesin as an i.v. push every 4 weeks. "
11/01/2003 - "AT-rich minisatellites (AT islands) are sites of genomic instability in cancer cells and targets for extremely lethal AT-specific drugs, such as bizelesin. "
11/02/2001 - "In cancer cells, bizelesin produced high levels of lesions (approximately 4.7-7.1 lesions/kilobase pair/microM drug) in several prominent AT islands, compared with markedly lower lesion levels in several motif-poor loci and in bulk cellular DNA (approximately 0.8-1.3 and approximately 0.9 lesions/kilobase pair/microM drug, respectively). "
05/17/1994 - "Human colon carcinoma cells were treated with adozelesin and bizelesin, and the position of adducts were mapped within the PGK-1 and p53 genes by means of ligation-mediated polymerase chain reaction. "
07/01/2003 - "The DNA minor groove-alkylating cyclopropylpyrroloindole drugs adozelesin and bizelesin induce different DNA damage response pathways in human colon carcinoma HCT116 cells."
12/15/1991 - "DNA damage and differential cytotoxicity produced in human carcinoma cells by CC-1065 analogues, U-73,975 and U-77,779."
05/01/2004 - "To address this question, HCT116 colon carcinoma cells have been treated with equally cytotoxic doses of the antitumor DNA alkylating agents adozelesin or bizelesin or the DNA strand scission agent C-1027. "
|4.||Hematologic Neoplasms (Hematological Malignancy)
05/01/2003 - "The characteristics of the myelosuppression, the paucity of severe toxicities with repetitive treatment, the preliminary antitumor activity noted, and, above all, its unique mechanism of action as a selective DNA-damaging agent and high potency, warrant disease-directed evaluations of bizelesin in solid and hematopoietic malignancies and consideration of its use as a cytotoxic in targeted conjugated therapeutics."
|2.||DNA (Deoxyribonucleic Acid)
|3.||Vinblastine (Vinblastine Sulfate)